enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM sets out a framework for patients to understand the basic genetic concepts behind the mutations that are important in WM, to appreciate the ways in which these mutations impact the signaling systems that control the behavior of WM cells, and to recognize how these mutations are changing the landscape of therapies for WM.

Read more..

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, of Dana-Farber Cancer Institute, discusses Bruton’s tyrosine kinase (BTK), which is activated during severe COVID-19 infection. Patients with the coronavirus and chronic lymphocytic leukemia who remained on the BTK inhibitor ibrutinib had a mild disease course, with decreased C-reactive protein and improved oxygenation. Clinical trials to validate the role of BTK inhibitors in treating COVID-19–related pulmonary distress are now underway.

Read more..

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Dr. Steven Treon delivered this on-line lecture on August 5, 2020 for the benefit of the WMFC Toronto Support Group. It is our privilige to share it with the entire WM community.  It focuses on the role of BTK Inhibitors in the treatment of Waldenstrom's Macroglobulinemia, and the advances being made based on the latest research.

Read more..

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the first installment in our 2020 IWMF Global Educational Webinar series.

Read more..

Waldenstrom Patient Stories: Finding Strength

Waldenstrom Patient Stories: Finding Strength

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

Read more..

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

Read more..

IWMF Virtual Educational Forum - August 27-28, 2020

IWMF Virtual Educational Forum - August 27-28, 2020

As most of you know, the 2020 IWMF Educational Forum will be virtual/online and is coming soon (August 27-28) - see agenda and registration details at: https://www.iwmf.com/news-and-events/iwmf-educational-forum.

Read more..

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC (the Canadian affiliate of the IWMF) was proud to have Dr. Zachary Hunter of the Dana-Farber Cancer Institute join the Atlantic Canada WM Support Group for a recent virtual meeting. Dr Hunter described the latest research into Waldenstrom’s macroglobulinemia. After his talk, he took questions from the participants and described the latest research project he is taking on with the financial backing of the WMFC, IWMF, LLS and the Leukemia Foundation of Australia.

Read more..

New Waldenstrom Macroglobulinemia Patient Story of Hope

New Waldenstrom Macroglobulinemia Patient Story of Hope

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Read more..

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.

Read more..